The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature
Lung cancer is the second most common cancer in both sexes worldwide. Small-cell lung cancer (SCLC) is a form of neuroendocrine tumor, which is classified into limited and extensive-stage disease and shows excellent initial response to chemotherapy; however, almost all patients relapse later. During...
Saved in:
Main Authors: | Ioanna Tsiouprou, Athanasios Zaharias, Dionisios Spyratos |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Canadian Respiratory Journal |
Online Access: | http://dx.doi.org/10.1155/2019/6860432 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluation of treatment strategies for patients with stage IIIA non-small cell lung cancer in the immunotherapy era
by: Amy Alabaster, et al.
Published: (2024-01-01) -
Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression
by: Jianfeng Peng, et al.
Published: (2025-02-01) -
Acute Interstitial Nephritis in a Patient with Non-Small Cell Lung Cancer under Immunotherapy with Nivolumab
by: Panagiotis I. Georgianos, et al.
Published: (2019-01-01) -
Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy
by: Dongyan Shi, et al.
Published: (2023-01-01) -
Anlotinib as Maintenance Therapy After First-Line Chemotherapy Combined with Consolidation Radiation for Extensive-Stage Small Cell Lung Cancer
by: Jinbo Ma MD, et al.
Published: (2025-01-01)